Typewriter Therapeutics has transitioned from stealth mode, announcing the successful completion of a $56 million Series A funding round. This round was co-led by AN Venture Partners and RA Capital Management, with additional investment from ANRI, Gemseki, and the SBI US Gateway Fund.
The company is pioneering RNA-based genetic therapies aimed at treating cancer, autoimmune disorders, and severe genetic diseases. Their approach utilizes a site-specific, non-viral gene insertion technology to deliver these innovative genetic medicines.
Key Leadership Changes
In conjunction with this funding announcement, Typewriter has appointed Matthew Stanton, Ph.D., as CEO, and Leanne Peiser, DPhil, as Chief Scientific Officer. Additionally, Mikael Dolsten, M.D., Ph.D., the former Chief Scientific Officer at Pfizer, has joined as an independent board director.
Innovative Therapeutic Platform
Typewriter’s therapeutic platform, known as Target-Primed Reverse Transcription, leverages the R2 retrotransposon—a naturally occurring gene insertion mechanism identified by the company’s academic co-founders.
The therapy comprises two distinct RNA components delivered via lipid nanoparticles. One mRNA encodes the R2 protein while the other contains the therapeutic gene. Inside the cell, these components combine to insert the gene at a predetermined genomic target. Once the insertion is complete, the R2 machinery and the mRNA degrade, ensuring precision and safety.
Focus Areas and Future Plans
Initially, Typewriter is concentrating on developing in vivo CAR T therapies and addressing genetic liver diseases. The company plans to commence non-human primate studies in late 2026, which is a significant step in validating their approach before moving to human trials.
This funding will facilitate the development of Typewriter’s first in vivo CAR T candidate, building on the proof-of-concept established in humanized mouse models.
Leadership Experience
Matthew Stanton brings a wealth of experience to his role, having previously served as a Venture Partner at RA Capital’s Raven incubator. He also spent seven years at Generation Bio, including five years as Chief Scientific Officer. His earlier experience includes a position as Vice President and Head of Chemistry at Moderna Therapeutics.
Leanne Peiser adds over two decades of expertise in biotech and pharmaceutical research and development, with a focus on autologous, allogeneic, and in vivo CAR T therapies. Most recently, she served as Executive Director of Translational Research in Cellular Therapy at Bristol Myers Squibb.
Additionally, Stanley R. Riddell, M.D., a renowned researcher from the Fred Hutchinson Cancer Center and co-founder of Juno Therapeutics, has joined Typewriter’s Scientific Advisory Board.
Vision for the Future of CAR-T Therapy
“Our technology aims to insert a durable, functional gene into a safe-harbor site in T cells using lipid nanoparticle-delivered RNA, allowing for safer and more accessible genetic medicines. This funding will help us advance the proof-of-concept work we’ve conducted in humanized mouse models and establish our first in vivo CAR T development candidate,” stated Matthew Stanton, Ph.D., CEO and Board Director of Typewriter Therapeutics.
Mikael Dolsten, M.D., Ph.D., expressed enthusiasm for the potential of Typewriter’s innovative approach. He highlighted that mRNA vaccines have demonstrated the viability of RNA-based medicines on a global scale. Typewriter takes this advancement further by utilizing RNA not merely to express temporary proteins, but to embed durable therapeutic genes at precise genomic locations without the use of viruses. This could revolutionize in vivo CAR T therapies, combining simpler administration with long-lasting CAR expression and the ability to re-dose, thereby enhancing patient safety and accessibility.
Conclusion
Typewriter Therapeutics stands at the forefront of a transformative approach to genetic medicine with its innovative funding and leadership. By harnessing the power of RNA in a non-viral framework, it aims to make advanced therapies accessible to a broader patient base. As they move toward clinical applications, the implications for cancer, autoimmune diseases, and genetic disorders could be profound.
- Typewriter Therapeutics has raised $56 million in Series A funding.
- The company focuses on RNA-based genetic medicines using non-viral gene insertion.
- Key appointments include Matthew Stanton as CEO and Leanne Peiser as Chief Scientific Officer.
- Initial targets include in vivo CAR T therapies and genetic liver diseases.
- The approach leverages the R2 retrotransposon for precise gene insertion.
Read more → pulse2.com
